Efficacy and safety of Rosalrestat and recombinant human erythropoietin in the treatment of chronic renal anemia
Objective To compare the efficacy and safety of Roxastat and recombinant human erythropoietin in the treatment of chron-ic renal anemia.Methods The clinical data of 178 patients with chronic kidney disease with anemia admitted to General Hospital of Northern Theater Command from June 1,2020 to December 31,2022 were retrospectively analyzed.Patients were divided into erythro-poietin group(n =88)and Rosallistat group(n =90)according to treatment.Erythropoietin group was injected subcutaneously with re-combinant human erythropoietin injection.Rosalrestat group took Rosalrestat capsules orally.Baseline data,anemia-related indicators before and after treatment,and adverse events were compared between the two groups.Results There was no significant difference in baseline data between the two groups(P>0.05).There was no significant difference in anemia related indexes between the two groups before and after treatment(P>0.05).The red blood cell count and hematocrit in the erythropoietin group after treatment were higher than those before treatment,and the red blood cell count,hemoglobin and hematocrit in the Rosallistat group after treatment were higher than those before treatment.According to the actual clinical situation,the two groups of patients received 14 days or 15 to 28 days of treatment.There was no significant difference in anemia related indexes between the two groups before treatment and 14 days after treatment(P>0.05).After 14 days of treatment,the red blood cell count,hemoglobin and hematocrit of the two groups were higher than those before treatment.There was no significant difference in red blood cell count,hemoglobin and hematocrit between two groups before treatment and 15 to 28 days after treatment(P>0.05).The red blood cell count,hemoglobin and hematocrit in the erythropoie-tin group after 15 to 28 days of treatment were higher than those before treatment.The red blood cell count,hemoglobin and hematocrit in Roxallistat group after 15 to 28 days of treatment were higher than those before treatment,and the differences were statistically sig-nificant(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Both Roxallistat and recombinant human erythropoietin can improve anemia in patients with chronic renal anemia,and Roxallistat is more effective in treatment.
NETL
NSTL
万方数据
维普
